University of Central Florida Music Study
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age50+
SponsorUniversity of Central Florida
About this trial
The purpose of this study is to scientifically validate the impact of music therapy on Alzheimer's disease (AD) by analyzing molecular biomarkers in salivary exosomes. Exosomes are extracellular vesicles that carry molecular signals from brain cells, providing a non-invasive method to assess physiological changes.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
50 years old or older.
20 adults with no mild-cognitive impairment
20 adults with mild-cognitive impairment
20 adults with Alzheimer's disease/ dementia.
Disqualifiers
49 years and younger
prisoners
unable to understand English and provide consent
Trial design
Design model
Single group
Treatments tested in this trial
Music intervention
Other interventionUCF music concert where the participants will listen to symphonic, classical music for 1 hour.
Treatment groups
60 Participants
are divided into 1 treatment groupGroup A: All participantsExperimental treatment 1 intervention
Trial outcomes
Primary outcomes
1
Effect of music therapy in Alzheimer's patients by analyzing salivary exosomes
To determine the effect of music therapy on key neurochemical biomarkers in Alzheimer's patients by analyzing serotonin, dopamine, amyloid-beta, and tau protein levels in salivary exosomes before and after music therapy sessions.
Time frame
6 monthsSecondary outcomes
1
Identifying therapeutic benefits by correlating changes in biomarkers
To establish a molecular basis for the therapeutic benefits of music therapy by correlating changes in biomarker levels with cognitive, emotional, and behavioral outcomes in AD patients.
Time frame
6 months2
Identify differences in individual participant biomarkers
To explore the potential for personalized music therapy by identifying individual differences in biomarker responses, which could guide tailored therapeutic interventions for optimal patient outcomes.
Time frame
6 monthsSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov